Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.5%

2 terminated out of 16 trials

Success Rate

84.6%

-1.9% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed with results

Key Signals

2 with results85% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (2)
P 1 (6)
P 2 (6)
P 4 (1)

Trial Status

Completed11
Terminated2
Withdrawn1
Unknown1
Recruiting1

Trial Success Rate

84.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT05986292Phase 2Recruiting

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

NCT06336486Not ApplicableCompletedPrimary

the Effectiveness of Intermittent Pneumatic Compression on Neuropathic Pain in Patients With Diabetic Polyneuropathy

NCT04471337Phase 1Completed

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT05406219Phase 1WithdrawnPrimary

A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function

NCT05563454Phase 1CompletedPrimary

A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants

NCT04265781Phase 1Completed

Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

NCT04487431Phase 1Completed

A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)

NCT04454424Phase 1Completed

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT02783469CompletedPrimary

Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)

NCT04137328Not ApplicableUnknownPrimary

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

NCT00619983Phase 4TerminatedPrimary

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00452777Phase 2CompletedPrimary

Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain

NCT01579279Phase 2TerminatedPrimary

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT00548925Phase 2CompletedPrimary

A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT01345045Phase 2CompletedPrimary

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01589432Phase 2CompletedPrimary

A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy

Showing all 16 trials

Research Network

Activity Timeline